Abstracts tagged "Inflammation"

Abstract Number: 0921 • ACR Convergence 2024
Deep Immunologic Profiling of Trisomy 8-associated Autoinflammatory Disease (TRIAD)
Kalpana Manthiram¹, Lihong Shi¹, Yue Zhang², Bayu Sisay³, Shouguo Gao⁴, Zhijie Wu⁴, Qin Xu¹, Mary Bowes², Laura Failla², Neelam Redekar², Abdel Elkahloun³, Pamela Schwartzberg¹ and Daniel Kastner³, ¹National Institute of Allergy and Infectious Disease, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, Bethesda, MD, ³National Human Genome Research Institute, Bethesda, MD, ⁴National Heart, Lung, and Blood Institute, Bethesda, MD
Background/Purpose: Trisomy 8 mosaicism is associated with an inflammatory disease characterized by recurrent fever and oral, genital, and gastrointestinal ulcers, resembling Behçet’s disease. Little is…
Abstract Number: 1198 • ACR Convergence 2024
Impact of Metabolic Syndrome on Knee Osteoarthritis Severity and Progression: A PROCOAC Cohort Study
Natividad Oreiro¹, Ana Raga², Vanesa Balboa-Barreiro³, Ignacio Rego-Perez⁴, Belen Acasuso⁵, Laura Galindo Domínguez⁶ and francisco J Blanco⁷, ¹CHUAC, La Coruna, Galicia, Spain, ²Grupo de Investigación en Reumatología (GIR). INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC). SERGAS, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Instituto de Investigacion Biomedica de A Coruña-SERGAS, A Coruña, Spain, ⁵Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ⁶Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ⁷INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: The contribution of metabolic factors to the development of osteoarthritis (OA) has not been fully elucidated. The aim of this study is to analyze…
Abstract Number: 1712 • ACR Convergence 2024
Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment
Yulong Tang¹, Jiangnan Xie², Dachun Zhuo¹, Qi ZHU³, Jiucun Wang¹ and Jing Liu², ¹Fudan University, Shanghai, China (People's Republic), ²Fudan University, Shanghai, Shanghai, China (People's Republic), ³Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an autoimmune and auto-inflammatory disease characterized by chronic inflammation of the spine, sacroiliac joint, and occasionally peripheral joints. TNF-α inhibitor…
Abstract Number: 1991 • ACR Convergence 2024
Initial Corticosteroid Dosing and Effects on Disease Activity, Survival, and Tumor Progression in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Muhammad Bukhari¹, Ami Shah², Clifton Bingham³, Michelle Jones⁴ and Laura Cappelli¹, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Pittsburgh, PA
Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) occurs in 3-7% of patients receiving ICI therapy for cancer. ICI-IA is routinely treated with corticosteroids, however, there…
Abstract Number: 2314 • ACR Convergence 2024
Serum Calprotectin (S100A8/9) and Complement Factor C3 as Potential Inflammatory Markers in Obese and “CRP Negative” Early PsA Patients: Data from a Multicenter METAPSA Cohort
Alla Ishchenko¹, Margot Van Mechelen², Sofia Pazmino³, Lies Storms⁴, Patrick Verschueren⁵, Rik Lories⁶ and Kurt de Vlam⁷, ¹UZ Gasthuisberg, Leuven, Belgium, ²Antwerp University Hospital, Belgium, Antwerp, Belgium, ³KU Leuven University, Leuven, Belgium, Leuven, Belgium, ⁴KU Leuven, Leuven, Belgium, ⁵Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ⁶Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, ⁷Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium
Background/Purpose: Systemic inflammation is an integral part of psoriatic arthritis (PsA). Despite substantial inflammation in the affected tissues such as skin, entheses and joints, C-reactive…
Abstract Number: 2637 • ACR Convergence 2024
Chaperone-mediated Autophagy in Synovitis Distinguishes Psoriatic Arthritis from Rheumatoid Arthritis
Vincenzo Venerito¹, Gerardo Cazzato², Fabio Cacciapaglia³, Eleonora Ceglie⁴, Sergio Del Vescovo⁴, Teresa Caferri⁴, Giuseppe Lopalco⁴, Francesco Girolamo⁵ and Florenzo Iannone¹, ¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²Pathology Unit - University of Bari "Aldo Moro", IT, Bari, Italy, ³Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁴Rheumatology Unit - University of Bari "Aldo Moro", IT, Bari, Italy, ⁵Human Anatomy Department - University of Bari "Aldo Moro", IT, Bari, Italy
Background/Purpose: Recent studies have suggested that autophagy may play different roles in the pathogenesis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Lysosome-associated membrane protein type 2A…
Abstract Number: 0068 • ACR Convergence 2024
Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis
Yong-Wook Park¹, Ki-Jeong Park², Sungsin Jo³, Tae-Hwan Kim⁴ and Tae-Jong Kim¹, ¹Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ²Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton. T helper 17 (Th17) cells play a pivotal role in the…
Abstract Number: 0382 • ACR Convergence 2024
Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation
Ilaria Maccora¹, Mariia Pavlenko², Jackeline Rodriguez-Smith³, Amy Cassedy⁴, Mekibib Altaye⁵, hermine brunner⁶, Alexandra Duell⁵, Alexei Grom⁵, Theresa Hennard⁷, Virginia Miraldi Utz⁵, Najima Mwase⁵, Megan Quinlan-Waters⁵, grant schulert⁵, Alyssa Sproles⁸, Jessica Shantha⁹, Sunil K Srivastava¹⁰, Sherry Thornton⁸, Steven Yeh¹¹ and sheila Angeles-Han¹², ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁴Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital, Cincinnati, ⁹UCSF/Proctor Foundation, San Francisco, IL, ¹⁰Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
Abstract Number: 0775 • ACR Convergence 2024
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Löhr⁸, Nicolas Schleinitz⁹, Lingli Dong¹⁰, Hisanori Umehara¹¹, Marco Lanzillotta¹², Zachary Wallace¹³, Mikael Ebbo¹⁴, George Webster¹⁵, Ferran Martinez Valle¹⁶, Manu Nayar¹⁷, Vinciane Rebours¹⁸, Cory Perugino¹⁹, Xinxin Dong²⁰, Yanping Wu²⁰, Nishi Rampal²⁰ and Daniel Cimbora²⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Ospedale San Raffaele, Milan, Italy, ⁶University of Occupational and Environmental Health, Osaka, Japan, ⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹¹Department of Rheumatology and Immunology, Nagahama City Hospital,, Nagahama, Shiga 526-0043, Japan, Japan, ¹²IRCCS Ospedale San Raffaele, Milano, Italy, ¹³Massachusetts General Hospital, Newton, MA, ¹⁴Aix-Marseille Université, Marseille, France, ¹⁵University College Hospital London, London, United Kingdom, ¹⁶Vall d’Hebron Hospital, Barcelona, Spain, ¹⁷Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁸Beaujon Hospital, Université Paris-Cité, France, ¹⁹Massachusetts General Hospital, Boston, MA, ²⁰Amgen Inc., Thousand Oaks, CA
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 0923 • ACR Convergence 2024
Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde Modified Vimentin Induces Post-Translational Protein Modifications and Extracellular Matrix Deposition in Heart Tissues
Kimberley Sinanan¹, Wenxian Zhou², Michael Duryee¹, Nozima Aripova¹, Jill Poole¹, Carlos Hunter¹, Amy Nelson¹, Tate Johnson¹, Daniel Anderson³, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ³University of Nebraska Medical Center, Durham, NC
Background/Purpose: Recent studies have highlighted the importance of malondialdehyde-acetaldehyde (MAA)-modified proteins and resulting immune responses in the pathogenesis of rheumatoid arthritis (RA). MAA adducts have…
Abstract Number: 1206 • ACR Convergence 2024
Association of Effusion-synovitis on Knee Pain in Early and Later-stage Knee Osteoarthritis
Lindsey MacFarlane¹, Mike Paskewicz², Jamie Collins² and Jeffrey Katz², ¹Brigham and Women's Hospital, Hanover, NH, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Pain in knee osteoarthritis (OA) is associated with structural features including effusion-synovitis (E-S) and radiographic severity. Prior studies show a cross-sectional association between larger…
Abstract Number: 1730 • ACR Convergence 2024
Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors
Daniel Portnoy¹, Matthieu J Piola², Luke Hao², Robert Winchester², Adam Mor² and Yevgeniya Gartshteyn³, ¹Columbia University Irving Medical Center, New Yok, NY, ²Columbia University Irving Medical Center, New York, NY, ³Columbia University Irving School of Medicine, New York, NY
Background/Purpose: Inflammatory arthritis is one of the most common immune-related adverse events (irAEs) resulting from immune checkpoint inhibitors (ICIs). We hypothesized that T cells present…
Abstract Number: 1993 • ACR Convergence 2024
Identification of Elevated Soluble Factors in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Their Association with Severity and Persistence
Elise Gray-Gaillard¹, Clifton Bingham¹, Ami Shah² and Laura Cappelli³, ¹Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) are a type of cancer immunotherapy being implemented as the standard of care for an increasing number of malignancies. Due…
Abstract Number: 2362 • ACR Convergence 2024
Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Lianne S Gensler¹, Helena Marzo-Ortega², Vanessa Taieb³, Diana Voiniciuc⁴, Alexander Marten⁵, George Stojan⁶, Mindy Kim⁶ and Martin Rudwaleit⁷, ¹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³UCB Pharma, Colombes, France, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Atlanta, GA, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ has demonstrated sustained efficacy and safety to Week…
Abstract Number: 2643 • ACR Convergence 2024
Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
Kristina Clark¹, Corrado Campochiaro², Emma Derrett-Smith³, Voon Ong⁴, Christopher Buckley⁵ and Christopher Denton⁶, ¹University of Oxford, Oxford, United Kingdom, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³University College London Division of Medicine, Birmingham, United Kingdom, ⁴University College London, London, England, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁶University College London, Northwood, United Kingdom
Background/Purpose: Myofibroblasts are key cells in the pathogenesis of systemic sclerosis (SSc). TGFβ is a key growth factor driving myofibroblast formation in SSc. The main…

« Previous Page
1
…
4
5
6
7
8
…
58
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].